Detection of Trisomy 8 in Donor-Derived Ph⁻ Cells in a Patient with Ph⁺ Chronic Myeloid Leukemia Successfully Treated with Imatinib (STI571) in Relapse after Allogeneic Transplantation

Reference

• Sawyers, C.L. (1999) "Chronic myeloid leukemia", New England Journal of Medicine, 340, 1330 — 1340.
   PubMed Web of Science ®Google Scholar
• Vardiman, J.W., Pierre, R. and Thiele, J. (2001) Chronic myelogenous leukaemia. In Tumours of Haematopoietic and Lymphoid Tissues, Pathology & Genetics, World Health Organization Classification of Tumors, edited by E.S. Jaffe, N.L. Harris, H. Stein and J.W. Vardiman. Pp. 20–26. Lyon: IRAC Press.
   Google Scholar
• Faderl, S., Tapaz, M. and Estrov, Z. (1999) "The biology of chronic myelogenous leukemia", New England Journal of Medicine, 341, 164–172.
   PubMed Web of Science ®Google Scholar
• Gratwohl, A., Hermans, J. and Niederwieser, D. (1993) "Bone marrow transplantation for chronic myeloid leukemia", Bone Marrow Transplantation, 12, 509 — 516.
   Web of Science ®Google Scholar
• Clift, R.A., Applebaum, F.R. and Thomas, E.D. (1993) "Treatment of chronic myeloid leukemia by marrow transplantation", Blood, 82, 1954— 1956.
   Google Scholar
• Silver, R.T., Woolf, S.H. and Hehlmann, R. (1999) "An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology", Blood, 94, 1517 — 1536.
   Google Scholar
• Hehlmann, R., Heimpl, H., Hasford, J. and the German CML Study Group. (1994) "Randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia", Blood, 84, 4064–4077.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H.M., Smith, T.L., O'Brien, S. and the Leukemia Service (1995) "Prolonged survival in chronic myelogenous leuke-mia after cytogenetic response to interferon-a therapy", Annals of Internal Medicine, 122, 254 — 261.
   Google Scholar
• Ozer, H., George, S.L. and Schiffer, C.A. (1993) "Prolonged subcutaneous administration of rha2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583", Blood, 82, 2975–2984.
   Google Scholar
• Peggs, K. and Mackinnon, S. (2003) "Imatinib mesylate—the new gold standard for treatment of chronic myeloid leukemia", New England Journal of Medicine, 348, 1048–1050.
   Google Scholar
• Druker, B.J., Talpaz, M. and Resta, DJ. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", New England Journal of Medicine, 344, 1031 — 1037.
   Google Scholar
• O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., et al. (2003) "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia", New England Journal of Medicine, 348, 994 — 1004.
   Google Scholar
• Talpaz, M., Silver, R.T., Druker, B.J., Goldman, J.M., Gambacorti-Passerini, C., Guilhot, F., et al. (2002) "Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study", Blood, 99, 1928 — 1937.
   Web of Science ®Google Scholar
• Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D., Reese, S.F., Forde, J., et al. (2001) "Activity of specific inhibitor of the BCR-ABL tyrosine lcinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromo-some", New England Journal of Medicine, 344, 1038–1042.
   Google Scholar
• Wassmann, B., Klein, S.A., Scheuring, U., Pfeifer, H., Martin, H., Gschaidmeier, H., et al. (2001) "Hematologic and cytogenetic remission by 5TI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation", Bone Marrow Transplantation, 28, 721–724.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H.M., O'Brien, S., Cortes, J.E., Giralt, S.A., Rios, MB., Shan, J., et al. (2002) "Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia", Blood, 100, 1590— 1595.
   Google Scholar
• Olavarria, E., Craddock, C., Dazzi, F., Mann, D., Marktel, S., Apperley, J.F., et al. (2002) "Imatinib mesylate (5TI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation", Blood, 99, 3861–3862.
   PubMed Web of Science ®Google Scholar
• Vandenberghe, P., Boeckx, N., Ronsyn, E., Decorte, R., Verhoef, G. and Hagemeijer, A. (2003) "Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation", Leukemia, 17, 458–460.
   Google Scholar
• McCann, SR., Gately, K., Conneall, E. and Lawler, M. (2003) "Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML", Blood, 101, 1200–1201.
   Google Scholar
• Consoli, U., Milone, G., Guido, G., Consoli, C., Palombo, G.A. and Giustolisi, R. (2002) "5TI571 (GLIVEC) induced hematologic, cytogenetic and molecular remission in a CML patient relapsing with accelerated phase after allogeneic stem cell transplantation", Haematologica, 87, ECR37.
   Google Scholar
• Wassmann, B., Scheuring, U., Thiede, C., Pfeifer, H., Bornhauser, M., Griesinger, F., et al. (2003) "Stable molecular remission induced by imatinib mesylate (5TI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation", Bone Marrow Transplantation, 31, 611 — 614.
   Google Scholar
• Garcia-Manero, G., Faderl, S., O'Brien, S., Cortes, J., Talpaz, M. and Kantarjian, H.M. (2003) "Chronic myelogenous leukemia: a review and update of therapeutic strategies", Cancer, 98, 437 —457.
   Google Scholar
• Sillaber, C., Mayerhofer, M., Agis, H., Sagaster, V., Mannhalter, C., Sperr, W.R., et al. (2003) "Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts", Wiener Klinische Wochenschrift, 115, 485–504.
   PubMed Web of Science ®Google Scholar
• Giralt, S.A. and Kolb, H.J. (1996) "Donor lymphocyte infusions", Current Opinion in Oncology, 8, 96–102.
   PubMedGoogle Scholar
• Gambacorti-Passerini, C.B., Gunby, R.H., Piazza, R., Galietta, A., Rostagno, R. and Scapozza, L. (2003) "Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukae-mias", Lancet Oncology, 4, 75–85.
   Google Scholar
• von Bubnoff, N., Peschel, C. and Duyster, J. (2003) "Resistance of Philadelphia-chromosome positive leukemia towards the lcinase inhibitor imatinib (5TI571, Glivec): a targeted oncoprotein strikes back", Leukemia, 17, 829–838.
   PubMed Web of Science ®Google Scholar
• Stayer, P.B., Brezinschek, R., Linkesch, W., Sill, H. and Neume-ister, P. (2003) "Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia", Haematologica, 88, ECR29.
   Google Scholar
• Paterson, S.C., Smith, K.D., Holyoake, T.L. and Jorgensen, H.G. (2003) "Is there a cloud in the silver lining for imatinib?", British Journal of Cancer, 88, 983–987.
   Google Scholar
• Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Lai, J.L., Philippe, N., Facon, T., et al. (2002) "Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment", Blood, 100, 1014 — 1018.
   Google Scholar
• Feldman, E., Najfeld, V., Schuster, M., Roboz, G., Chadburn, A. and Silver, R.T. (2003) "The emergence of Ph—, trisomy 8 cells in patients with chronic myeloid leukemia treated with Imatinib mesylate", Experimental Hematology, 31, 702–707.
   PubMed Web of Science ®Google Scholar